Krebs Biochemicals Reports Q2 FY26 Loss; Unaudited Standalone Results Published
Krebs Biochemicals reported a net loss of ₹614.28 lakhs for Q2 FY26, with total income at ₹417.41 lakhs. The unaudited standalone results for the quarter and half year were approved and published.
The announcement of substantial net losses for both the quarter and half year will likely have a high negative impact on the company's stock performance and investor confidence.
The company reported a significant net loss of ₹614.28 lakhs for the second quarter and ₹1,146.71 lakhs for the half year ended September 30, 2025, indicating poor financial performance.
Krebs Biochemicals and Industries Limited has announced its unaudited standalone financial results for the second quarter and half year ended September 30, 2025. The Board of Directors approved these results in a meeting held on November 4, 2025. The results were subsequently published in Business Standard (English) and Prajasakti (Telugu) newspapers on November 5, 2025. Key financial highlights for the quarter ended September 30, 2025 (in ₹ lakhs): * Total Income from Operations (Net): ₹417.41 lakhs * Net Loss for the period after tax: ₹(614.28) lakhs * Basic and Diluted Earnings Per Share (EPS) of ₹10/- each: ₹(2.85) Key financial highlights for the half year ended September 30, 2025 (in ₹ lakhs): * Total Income from Operations (Net): ₹966.67 lakhs * Net Loss for the period after tax: ₹(1,146.71) lakhs * Basic and Diluted Earnings Per Share (EPS) of ₹10/- each: ₹(5.32)
What to do with a filing like this
Krebs Biochemicals and Industries Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Krebs Biochemicals and Industries Limited. Read the original for the full detail.